Skyhawk Doses First U.S. Patients in Pivotal Huntington's Trial
Image
BOSTON – November 06, 2026 -- Skyhawk Therapeutics has dosed the first U.S. patients in its global pivotal FALCON-HD study of SKY-0515 in Huntington's disease (HD). More than 50,000 doses have been administered to date across more than 30 study sites in 10 countries.
CenExel Colorado site opens U.S. dosing, with Beth Israel Deaconess next
Dosing in the U.S. began at the CenExel Movement Disorder Center in Colorado. Additional U.S. sites, including Beth Israel Deaconess Medical Center, are expected to begin dosing in the coming weeks. Samuel Frank, MD, Director of the HDSA Center of Excellence at Beth Israel Deaconess and a FALCON-HD investigator, expects dosing there before the end of 2026. He described Phase 1/2 results to date as very encouraging.